$890,000.00 in Sales Expected for Spero Therapeutics Inc (SPRO) This Quarter

Brokerages forecast that Spero Therapeutics Inc (NASDAQ:SPRO) will announce sales of $890,000.00 for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Spero Therapeutics’ earnings. The highest sales estimate is $1.28 million and the lowest is $400,000.00. Spero Therapeutics posted sales of $990,000.00 in the same quarter last year, which would indicate a negative year-over-year growth rate of 10.1%. The company is scheduled to announce its next quarterly earnings results on Monday, April 1st.

According to Zacks, analysts expect that Spero Therapeutics will report full-year sales of $3.20 million for the current financial year, with estimates ranging from $2.67 million to $3.55 million. For the next year, analysts expect that the firm will report sales of $11.80 million, with estimates ranging from $7.50 million to $18.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last issued its earnings results on Thursday, November 8th. The company reported ($0.60) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.04. Spero Therapeutics had a negative net margin of 1,402.91% and a negative return on equity of 52.22%. The firm had revenue of $0.66 million during the quarter, compared to the consensus estimate of $0.66 million.

Several brokerages have commented on SPRO. Cantor Fitzgerald set a $27.00 target price on shares of Spero Therapeutics and gave the company a “buy” rating in a research note on Thursday, September 27th. Oppenheimer set a $30.00 target price on shares of Spero Therapeutics and gave the company a “buy” rating in a research note on Sunday, September 30th. Zacks Investment Research downgraded shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 17th. Finally, Bank of America downgraded shares of Spero Therapeutics from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $19.00 to $9.00 in a research note on Tuesday, October 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $20.70.

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC bought a new stake in shares of Spero Therapeutics during the third quarter worth $126,000. PNC Financial Services Group Inc. bought a new stake in shares of Spero Therapeutics during the second quarter worth $146,000. Millennium Management LLC bought a new stake in shares of Spero Therapeutics during the first quarter worth $163,000. Highland Capital Management LP bought a new stake in shares of Spero Therapeutics during the third quarter worth $210,000. Finally, Bank of New York Mellon Corp increased its position in shares of Spero Therapeutics by 73.9% during the second quarter. Bank of New York Mellon Corp now owns 24,689 shares of the company’s stock worth $363,000 after acquiring an additional 10,490 shares in the last quarter. 52.93% of the stock is owned by institutional investors.

Shares of NASDAQ:SPRO opened at $6.75 on Friday. Spero Therapeutics has a 52 week low of $6.45 and a 52 week high of $19.00. The company has a market capitalization of $123.37 million and a price-to-earnings ratio of -0.38.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

Further Reading: What is the LIBOR?

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply